Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

NewCardio Study Shows CardioBip Detects Recurrent Atrial Fibrillation Earlier and More Reliably than Periodic Holter Monitoring

February 24, 2011 3:35 am | News | Comments

SANTA CLARA, Calif., Feb. 24, 2011 /- PR Newswire – NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited by the Heart Rhythm Society (HRS) to present results of a recent clinical study showing...

Vilcek Foundation names recipients of 2011 Vilcek Prizes in Biomedical Science

February 24, 2011 1:37 am | by EurekAlert | News | Comments

(Vilcek Foundation) The Vilcek Foundation is pleased to announce the 2011 winners of its annual prizes honoring the contributions of foreign-born scientists and artists in the US. Titia de Lange, Ph.D., of Rockefeller University, takes the Vilcek Prize for Biomedical Science for...

TOPICS:

Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference

February 24, 2011 1:35 am | by Bio-Medicine.Org | News | Comments

BLUE BELL, Pa., Feb. 24, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO will present a company overview at the...

TOPICS:
Advertisement

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results

February 24, 2011 1:35 am | by Bio-Medicine.Org | News | Comments

THE WOODLANDS, Texas, Feb. 24, 2011 /- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three...

TOPICS:

Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer

February 23, 2011 10:35 pm | by Bio-Medicine.Org | News | Comments

WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar®...

TOPICS:

Volcano Reports Record Revenue and GAAP Profitability for 2010

February 23, 2011 10:33 pm | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Feb. 23, 2011 /- Volcano Corporation (Nasdaq: VOLC ), a leading developer and manufacturer of precision intravascular diagnosis and therapy guidance tools designed to enhance the treatment of coronary and peripheral vascular disease, today reported record revenues for the...

TOPICS:

Prevalence of bunions increases with age; more common in women

February 23, 2011 7:37 pm | by EurekAlert | News | Comments

(Wiley-Blackwell) New research determined that an increase in the severity of hallux valgus, or bunion deformity, progressively reduced both general and foot-specific health related quality of life. Bunion deformity was found in 36 percent of the study population and occurred more...

TOPICS:

Monocrystal ships 8-inch C-plane sapphire substrates to leading LED maker

February 23, 2011 7:36 pm | by I-Micronews | News | Comments

Monocrystal, announced the shipment of its premium 8-inch C-plane epi-ready sapphire substrates to what the company says is one of the world?s leading LED manufacturers.

Advertisement

Transphorm emerges from stealth to redefine energy efficiency

February 23, 2011 7:36 pm | by I-Micronews | News | Comments

Company backed by $38 million from leading venture capital firms Kleiner Perkins, Google Ventures, Foundation Capital, and Lux Capital.

Social Networking's Newest Friend: Genomics

February 23, 2011 7:33 pm | by Massachusetts Institute of Technology | News | Comments

The first large-scale study to combine genome sequencing and social-network analysis solves a mysterious TB outbreak.

TOPICS:

Serious Eye Disease Gives Birth to Invention of Major New Eye Care Device

February 23, 2011 5:35 pm | by Bio-Medicine.Org | News | Comments

ORLANDO, Fla., Feb. 23, 2011 /- The Eye-POD-Eye-Care-Kit was created by a Doctor who suffered a serious eye malady, Bells-Palsy. Inventor Dr. Courtenay created the Eye ~ POD™ to answer his struggles with dry eyes, a side effect of Bells-Palsy. The affliction was caused by scratching...

TOPICS:

New vaccine technology protects mice from hepatitis C virus

February 23, 2011 1:37 pm | by EurekAlert | News | Comments

(University of Copenhagen) HCV mutates so strongly that traditional vaccines are useless. However, University of Copenhagen researchers are the first to succeed in developing a vaccine, which provides future hope for medical protection from the hepatitis C virus.

TOPICS:

Support the Have a HeArt Benefit, Feb. 25

February 23, 2011 12:35 pm | by Arizona State University | News | Comments

ASU's College of Nursing & Health Innovation is hosting a "Have a HeART Benefit," Feb. 25, with proceeds going to the College's NP Healthcare Clinics.read more

TOPICS:

Review highlights need for more education and guidance on CAM use in midwifery

February 23, 2011 10:38 am | by EurekAlert | News | Comments

(Wiley-Blackwell) Complementary and alternative medicine is increasingly popular in maternity care, but health care professionals need formal evidence-based education and guidance about its use. University-based members of the Network of Researchers in the Public Health of...

TOPICS:

ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software

February 23, 2011 10:36 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, Feb. 23, 2011 /- ViewRay™, Inc., a privately held medical device company, has received U.S. FDA marketing clearance for its radiotherapy treatment planning and delivery software. The software is a critical component of the company's new radiation therapy system, which...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading